Will the Parkinson’s disease worth of KRW 20 billion be open to the market?

The patent lawsuit of a Parkinson’s disease treatment recording KRW 20 billion annually has attracted attention of the pharmaceutical industry.

Stalevo(entacapone/carbidopa/levodopa) sold by Novartis is the most prescribed drug in dementia and parkinson’s disease along with Aricept.

Unlike other competing drugs whose generics are already out in the market due to expiration in their patients, ...